Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Cardellino

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2008
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancerF Puglisi, G G Cardellino, D Crivellari, et al.
ESMO Open|January 4, 2025
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI)M Reni, M Milella, F Bergamo, et al.
ESMO Open|February 2, 2023
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI surveyM Reni, E Giommoni, F Bergamo, et al.
Journal of Cachexia, Sarcopenia and Muscle|February 6, 2019
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patientsDebora Basile, Annamaria Parnofiello, Maria Grazia Vitale, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|October 10, 2024
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI surveyM Reni, E Giommoni, F Bergamo, et al.
Breast Cancer Research and Treatment|February 12, 2022
Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analysesE Palassini, O Mir, G Grignani, et al.
ESMO Open|June 20, 2025
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trialR Fazio, G Randon, F Bergamo, et al.
Cancers|July 2, 2021
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY StudyAlessandra Raimondi, Federica Palermo, Michele Prisciandaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2024
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONOA Raimondi, S Lonardi, S Murgioni, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2008
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancerF Puglisi, G G Cardellino, D Crivellari, et al.
ESMO Open|January 4, 2025
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI)M Reni, M Milella, F Bergamo, et al.
ESMO Open|February 2, 2023
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI surveyM Reni, E Giommoni, F Bergamo, et al.
Journal of Cachexia, Sarcopenia and Muscle|February 6, 2019
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patientsDebora Basile, Annamaria Parnofiello, Maria Grazia Vitale, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|October 10, 2024
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI surveyM Reni, E Giommoni, F Bergamo, et al.
Breast Cancer Research and Treatment|February 12, 2022
Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analysesE Palassini, O Mir, G Grignani, et al.
ESMO Open|June 20, 2025
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trialR Fazio, G Randon, F Bergamo, et al.
Cancers|July 2, 2021
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY StudyAlessandra Raimondi, Federica Palermo, Michele Prisciandaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2024
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONOA Raimondi, S Lonardi, S Murgioni, et al.
Pageof 2